ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.473,63
1,32%
S&P 500
5.747,07
0,03%
Dow Jones
42.400,88
0,54%
Euro vs US Dollar
1,11579
-0,16%
Bitcoin
65.938,72
1,16%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. Bristol Myers Squibb Co (BMY)

  7. Bristol Myers Squibb Co (BMY) News

BMY

Bristol Myers Squibb (BMY)

Bristol Myers Squibb Co
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:BMY
DatumZeitQuelleÜberschriftSymbolFirma
27/09/202417h06Business WireBristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World SettingNYSE:BMYBristol Myers Squibb Co
27/09/202403h05Business WireU.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in AdultsNYSE:BMYBristol Myers Squibb Co
18/09/202412h59Business WireNew Long-Term Zeposia (ozanimod) Data Demonstrate Durable Efficacy and Consistent Safety in Relapsing Forms of Multiple SclerosisNYSE:BMYBristol Myers Squibb Co
15/09/202414h55Business WireBristol Myers Squibb Presents Landmark 10-Year Follow-Up Data from CheckMate -067 Which Showed Continued Durable Long-Term Survival Benefit with Opdivo® plus Yervoy® in Advanced MelanomaNYSE:BMYBristol Myers Squibb Co
12/09/202412h59Business WireBristol Myers Squibb to Report Results for Third Quarter 2024 on October 31, 2024NYSE:BMYBristol Myers Squibb Co
10/09/202423h45Business WireBristol Myers Squibb Announces DividendNYSE:BMYBristol Myers Squibb Co
09/09/202412h59Business WireBristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research PlatformsNYSE:BMYBristol Myers Squibb Co
06/09/202413h00Business WireBristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer ResearchNYSE:BMYBristol Myers Squibb Co
01/09/202409h33Business WireLong-Term Follow-Up Data from Phase 3 Study of CAMZYOS® (mavacamten) Underscores Established Efficacy and Safety Profile in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)NYSE:BMYBristol Myers Squibb Co
27/08/202412h59Business WireBristol Myers Squibb to Participate in Upcoming Investor ConferencesNYSE:BMYBristol Myers Squibb Co
26/08/202412h59Business WireBristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024NYSE:BMYBristol Myers Squibb Co
23/08/202414h20IH Market NewsCruise and Uber Join Forces for Robotaxis, Alibaba Shifts Primary Listing to Hong Kong, Altria Hikes Dividend 4.1%NYSE:BMYBristol Myers Squibb Co
21/08/202412h59Business WireBristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular CarcinomaNYSE:BMYBristol Myers Squibb Co
19/08/202412h59Business WireEuropean Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular LymphomaNYSE:BMYBristol Myers Squibb Co
30/07/202412h00IH Market NewsToyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom ChatbotsNYSE:BMYBristol Myers Squibb Co
26/07/202412h59Business WireBristol Myers Squibb Reports Second Quarter Financial Results for 2024NYSE:BMYBristol Myers Squibb Co
26/07/202412h08IH Market NewsU.S. Index Futures Point to Higher Open, Oil Prices DownNYSE:BMYBristol Myers Squibb Co
26/07/202411h57IH Market NewsDexcom Shares Drop 37% on Weak Revenue and Forecast; Coursera Rises 24% After Beating Q2 Revenue EstimatesNYSE:BMYBristol Myers Squibb Co
19/07/202412h59Business WireBristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular CarcinomaNYSE:BMYBristol Myers Squibb Co
08/07/202412h59Business WireBristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation DayNYSE:BMYBristol Myers Squibb Co
22/06/202401h30Business WireBristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)NYSE:BMYBristol Myers Squibb Co
21/06/202412h59Business WireEuropean Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous NivolumabNYSE:BMYBristol Myers Squibb Co
20/06/202412h59Business WireBristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024NYSE:BMYBristol Myers Squibb Co
18/06/202422h16Business WireBristol Myers Squibb Elects Michael R. McMullen to Board of DirectorsNYSE:BMYBristol Myers Squibb Co
18/06/202412h59Business WireBristol Myers Squibb Announces DividendNYSE:BMYBristol Myers Squibb Co
13/06/202422h46Business WireU.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid TumorsNYSE:BMYBristol Myers Squibb Co
04/06/202414h00Business WireBristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW TrialNYSE:BMYBristol Myers Squibb Co
04/06/202412h59Business WireBristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:BMYBristol Myers Squibb Co
03/06/202416h13Business WireBristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual MeetingNYSE:BMYBristol Myers Squibb Co
03/06/202414h00Business WireBristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung CancerNYSE:BMYBristol Myers Squibb Co
 Showing the most relevant articles for your search:NYSE:BMY

Kürzlich von Ihnen besucht

BIT
I07882
Intesa Sanpaolo
NASDAQ
SRSAW
Sarissa Capital Acquisit...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten